OTHER PUBLICATIONS & ABSTRACTS
Other Data
Evidence / Other
Identification of Racial Disparities (ESMO 2024)
Title: Identification of racial disparities across MammaPrint® and BluePrint® subtypes in HR+HER2- breast cancer Publication: ASCO 2024, Abstract #534 Authors: Sonya Reid, M.D., Jennifer G. Whisenant, Ph.D.; Jennifer Wei, M.D., Ph.D., Harshini Ramaswamy, M.Sc., Nicole Stivers, Ph.D., Andrea Menicucci, Ph.D., William Audeh, M.D., Tuya Pal, M.D. Background: Black women in Read More
Case Report: pCR to NAC + Pembro in High Risk Basal-type BC
Cureus, part of Springer Nature Author: Jiang et al.
Read MoreCost Effectiveness of MammaPrint in Brazil
The Breast 76 (2024) 103752 Author: Mansani et al.
Read MoreCost consequence model of MammaPrint in Germany
: Cost consequence model of the MammaPrint® (70-gene signature) and 21-gene signature in Patients with primary HR+ HER2-, N1 early-stage breast cancer in Germany
Read MoreNeoadjuvant CT Recommendations in Black women – SSO 2024
SSO 2024 Author: Solis-Pomales et al.
Read MoreNeoadjuvant CT & Immunotherapy in HR+/HER2-negative breast cancer
Journal of Clinical Oncology, April 9, 2024 Presenter: Rios-Hoyo et al.
Read MoreIMPRINT-TN: Triple-Negative Breast Cancer, Unlikely to Respond to Immunotherapy
2024 European Breast Cancer Conference (EBCC) (Abstract 2LBA) Presenter: Wolf et al.
Read More